WVE 8-K SEC Filing Analysis

Latest settled — T+20d ⚠ clustered

WVE ▼ -15.69% at T+20d

LONG call ✗ call lost -15.69% · α vs SPY -21.15% · entry $7.52 → $6.34

Next anchor: T+60d in 6w

Last close $5.70 (close Jun 8) · -24.20% from $7.52 entry

Entry anchored
Apr 28, 2026
via day open

T+1d

-6.25%

call -6.25% · α -6.24%

$7.05

settled 6w ago

T+5d

-4.52%

call -4.52% · α -6.21%

$7.18

settled 5w ago

T+20d

-15.69%

call -15.69% · α -21.15%

$6.34

settled 14d ago

T+60d

—

call — · α —

—

in 6w

Price Chart

Loading chart...

Executive Summary

Wave Life Sciences reported Q1 2026 EPS of -$0.13, beating consensus estimates of -$0.34 by 61.8%, and revenue of $38.2M (up 316% YoY from $9.2M). The beat was driven by higher milestone revenue from the GSK collaboration, while pipeline progress for obesity candidate WVE-007 (FDA-accepted Phase 2a) and RNA editing program WVE-006 (upcoming data) reinforced the bullish thesis.

Actionable Insight

The strong EPS beat and increased revenue, combined with positive pipeline catalysts (WVE-007 Phase 2a initiation, WVE-006 data in May), support a bullish near-term outlook. Watch for the May 18 investor webcast for RestorAATion-2 data and Phase 2a enrollment start for INLIGHT.

Key Facts

Q1 2026 revenue $38.2M vs $9.2M YoY, up 316%
Net loss per share -$0.13 vs -$0.29 YoY; beat consensus -$0.34 by 61.8%
Cash and cash equivalents $544.6M, runway into 3Q 2028
FDA accepted Phase 2a multidose portion of INLIGHT trial for WVE-007 (obesity); initiation on track for 2Q 2026
RestorAATion-2 data for WVE-006 (AATD) to be presented in May 2026, with regulatory feedback on accelerated approval expected mid-2026
GSK collaboration milestone payments contributed to revenue growth

Financial Impact

EPS beat of $0.21 vs consensus, revenue surge of $29M YoY

epsrevenuecash

Risk Factors

Clinical trial failures or delays for WVE-007 or WVE-006
Regulatory setbacks on accelerated approval pathway for WVE-006
Cash burn rate may accelerate with Phase 2a expansion
Competition from GLP-1 drugs in obesity market

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

95% bullish (20 analysts)

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001193125-26-183563
Document: d135689dex992.htm	0001193125-26-183563
Document: d135689d8k.htm	0001193125-26-183563
Document: 0001193125-26-183563-index-headers.html	0001193125-26-183563
Document: 0001193125-26-183563-index.html	0001193125-26-183563
Document: 0001193125-26-183563.txt	0001193125-26-183563
8-K Data (Synthetic)	0001193125-26-183563

8 reports for WVE

T+1T+5T+20T+60

67% Hit rate 2 of 3 directional calls best @ T+5▲ +17.42%Mar 26, 2026

Filters

Reports for WVE — sortable, filterable
	Type				Now
May 18, 2026 22d ago	Press Release BULLISH ★ 7/10	$6.14 $6.44	▲ +4.80%	▲ +2.56%	$5.70 (−7.17%)
Apr 28, 2026 6w ago	8-K BULLISH ★ 7/10	$7.52 $7.18	▼ −4.52%	▼ −6.21%	$5.70 (−24.20%)
Apr 28, 2026 6w ago	Press Release BULLISH ★ 7/10	$7.52 $7.47	▼ −0.66%	▼ −2.36%	$5.70 (−24.20%)
Apr 22, 2026 6w ago	Press Release NEUTRAL ★ 4/10	$7.38 $7.21	▼ −2.30%	▼ −2.36%	$5.70 (−22.76%)
Apr 15, 2026 7w ago	DEFA14A NEUTRAL ★ 4/10	$7.32 $7.31	▼ −0.14%	▼ −1.12%	$5.70 (−22.13%)
Apr 15, 2026 7w ago	8-K NEUTRAL ★ 5/10	$7.32 $7.31	▼ −0.14%	▼ −1.12%	$5.70 (−22.13%)
Mar 26, 2026 10w ago	Press Release BULLISH ★ 8/10	$6.20 $7.28	▲ +17.42%	▲ +15.79%	$5.70 (−8.06%)
Feb 26, 2026 14w ago	8-K MIXED ★ 7/10	$15.36 $13.20	▼ −14.06%	▼ −12.94%	$5.70 (−62.89%)

US Market Status

Market Closed — Opens in 7h 21m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access